AB
LENZ

Amalgamated Bank’s LENZ Therapeutics LENZ Stock Holding History

Amalgamated Bank’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-508
Closed -$8K – 2845
2025
Q4 		$8K Buy
508
+74
+17% +$2.16K ﹤0.01% 2553
2025
Q3 		$20K Hold
434
– – ﹤0.01% 2136
2025
Q2 		$13K Hold
434
– – ﹤0.01% 2335
2025
Q1 		$11K Buy
434
+299
+221% +$7.36K ﹤0.01% 2351
2024
Q4 		$4K Hold
135
– – ﹤0.01% 2818
2024
Q3 		$3K Hold
135
– – ﹤0.01% 2916
2024
Q2 		$2K Hold
135
– – ﹤0.01% 2970
2024
Q1 		$3K Sell
135
-214
-61% -$4.45K ﹤0.01% 2855
2023
Q4 		$6K Sell
349
-40
-10% -$660 ﹤0.01% 2933
2023
Q3 		$7K Hold
389
– – ﹤0.01% 2953
2023
Q2 		$7K Buy
+389
New +$7.77K ﹤0.01% 2987
2022
Q2 		– Sell
-597
Closed -$21K – 3225
2022
Q1 		$21K Buy
+597
New +$37.3K ﹤0.01% 2801

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

Amalgamated Bank's LENZ Position: Q1 2026 in Review

Amalgamated Bank sold out of LENZ Therapeutics (LENZ) in Q1 2026, closing a stake of 508 shares — an estimated $8K sold.

Amalgamated Bank first reported a position in LENZ in Q1 2022 and held it in 12 quarters. The position peaked at $21K in Q1 2022. 145 funds tracked by Wall St. Rank hold LENZ as of Q1 2026.

  • Amalgamated Bank reported no remaining LENZ Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Amalgamated Bank sold 508 LENZ Therapeutics shares in Q1 2026, an estimated $8K.
  • Amalgamated Bank first reported a position in LENZ Therapeutics in Q1 2022 and held it in 12 quarters.
  • Amalgamated Bank's LENZ Therapeutics position peaked at $21K in Q1 2022.
  • 145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.